PATENT CLAIM ANALYSIS

Application Number: 16291264
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["435", "007210"]

Abstract:
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.

Claim (Index 12):
The method of  claim 10 , comprising monitoring a treatment with an anti-p217+ tau antibody in a subject, the method comprising:\n (i) obtaining a biological sample from the subject, (ii) obtaining a semi-denatured sample from the biological sample containing total p217+ tau peptides, wherein the semi-denatured sample is heated to denature the antibodies in the sample, and obtaining a non-denatured sample from the biological sample containing p217+ tau peptides free of the anti-p217+ tau antibody, (iii) contacting each of the semi-denatured sample and the non-denatured sample with a capture antibody directed against a p217+ tau epitope to capture p217+ tau peptides in each of the samples, (iv) conducting at least one of (a) contacting the captured p217+ tau peptides with a first detection antibody directed against an epitope comprising amino acid residues 119 to 126 of tau protein to thereby measure an amount of p217+ tau peptides in each of the samples, and (b) contacting the captured p217+ tau peptides with a second detection antibody directed against an epitope comprising amino acid residues 7 to 20 of tau protein to thereby measure an amount of long p217+ tau peptides in each of the samples, optionally (c) determining an amount of short p217+ tau peptides via subtracting the amount of the long p217+ tau peptides from the amount of the p217+ tau peptides in each of the first and third samples, and (v) monitoring the treatment with the anti-p217+ tau antibody based on at least one of the amount of the p217+ tau peptides, the amount of the long p217+ tau peptides, the amount of the short p217+ tau peptides, and ratios thereof, in each of the samples.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 99.0
- Lexical Diversity: 1.66667
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15337964', '15750982', '16291303', '14348918', '14154954']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5969954568385031
- 35 USC 102 Novelty (BERT): 0.5322353319255182
- Combined Prediction Score: 0.5905194443472046
- Mean Citation Score: 343.305048
- Max Citation Score: 355.36682
- Similarity Product: 248.6047500443864

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test